Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2019

View Archived Issues

Interim phase II data presented for tazemetostat patients with follicular lymphoma

New BALB/c-hCD3E mouse model for evaluating the therapeutic efficacy of T-cell bispecific Abs

Results for dose-optimization phase of PRIMO trial of duvelisib in patients with R/R PTCL

Transplantation with MGTA-456 results in complete engraftment and rapid recovery

Janssen presents results from phase II trials of JNJ-42165279

UBA1 as a potent and druggable target in TNBC

Praxis Precision Medicines patents voltage-gated sodium channel blockers

Washington University patent describes MAPK inhibitors

Vanderbilt University reports RAS GTPase inhibitors

Muscarinic M1 receptor PAMs reported in Vanderbilt University patent

GABRA5 positive allosteric modulators designed at Roche

Oral compound ameliorates beta-thalassemia

By spying on quorum sensing, immune system picks its battles

China NMPA approves Sinovac's varicella vaccine

Remimazolam tosylate obtains first approval in China

Tislelizumab approved in China for classical Hodgkin's lymphoma

AstraZeneca begins first-in-human study of AZD-0466

Phase III MOMENTUM trial of AXS-08 for migraine meets coprimary endpoints

FDA approves Lynparza as first-line maintenance treatment for gBRCAm metastatic pancreatic cancer

Wave reports topline data from ongoing phase Ib/IIa study of WVE-120102 for Huntington's disease

Eli Lilly initiates phase III trial with selpercatinib in RET-mutant medullary thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...